雷帕鸣在国内有吗？

(sirolimus) is a new type of immunosuppressant developed by Wyeth Company of the United States. Clinical studies on early kidney transplant patients have shown the dual effects of sirolimus. Converting cyclosporine to sirolimus (rapamin) can result in complete regression of Kaposi's tumors in patients after kidney transplantation, while maintaining normal function of the transplanted kidney.

Currently, the drug is already on the market in China. Due to the different specifications of Leipaming, there will be certain differences in the final selling price. It is worth noting that Rapamin has now been included in the medical insurance catalog and is a Class B drug in the medical insurance. This means that when patients purchase the drug in China, they can rely on medical insurance to reimburse part of the cost, thus reducing their out-of-pocket expenses and easing their own financial burden.

However, for many domestic patients with limited financial conditions, it is still difficult to afford even after medical insurance reimbursement. For this reason, patients can contact some domestic professional overseas medical service institutions (such as Medical Companion Travel) to obtain more cost-effective drugs. Among them, India Biocon's Rapamin is very cost-effective. Since this version of the drug is currently only available overseas, patients in need are currently unable to purchase India Biocon's Rapamin in major hospitals and pharmacies in China. However, patients can obtain specific overseas drug purchase channels through Medical Companion Travel.

Leveraging India's globally competitive cost base and outstanding scientific research talent, Biocon India is advancing its in-house R&D projects and integrated research services, and also provides global leading pharmaceutical and biotechnology. Clinical Development (Clinigene) and Biopharmaceuticals (Biocon) provide multiple revenue streams to balance risk, drive innovation, deliver products and accelerate growth, increasing the complexity and scope of their own R&D and manufacturing operations, particularly in the discovery and development of new products. India's Biocon has now been successfully launched overseas.

Recommended hot articles: Yin /newsDetail/92395.html